Cellular HIV type 1 DNA levels are equivalent among drug-sensitive and drug-resistant strains in newly diagnosed and antiretroviral naive patients

AIDS Research and Human Retroviruses

Volumn 30, Issue 3, 2014, Pages 266-271

  Antoniadou, Zoi Anna ^a   Hezka, Johana ^b   Kousiappa, Ioanna ^b   Mamais, Ioannis ^b   Skoura, Lemonia ^a   Pilalas, Dimitris ^c   Metallidis, Simeon ^c   Nicolaidis, Pavlos ^c   Malisiovas, Nicolaos ^a   Kostrikis, Leondios G ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY OF CYPRUS   (Cyprus)

^c AHEPA UNIVERSITY HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS DNA; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DISEASE COURSE; DNA SEQUENCE; FEMALE; GENOTYPE; GREECE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MOLECULAR BEACON; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; TROPISM;

ADULT; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GREECE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MOLECULAR SEQUENCE DATA; PROVIRUSES; SEQUENCE ANALYSIS, DNA; VIRAL LOAD; VIRAL TROPISM;

EID: 84895532050     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2013.0160     Document Type: Article

References (41)

1. Gulick RM, Mellors JW, Havlir D, et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337(11):734-739.
2. Hammer SM, Squires KE, Hughes MD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337(11):725-733.
3. Hughes MD, Johnson VA, Hirsch MS, et al.: Monitoring plasma HIV-1 RNA levels in addition to CD4 + lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. Ann Intern Med 1997;126(12):929-938.
4. Katzenstein DA, Hammer SM, Hughes MD, et al.: The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med 1996;335(15):1091-1098.
5. O'Brien WA, Hartigan PM, Martin D, et al.: Changes in plasma HIV-1 RNA and CD4 + lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. N Engl J Med 1996;334(7):426-431.
6. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, and Kingsley LA: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272(5265):1167-1170.
7. Descamps D, Chaix ML, Andre P, et al.: French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002. J Acquir Immune Defic Syndr 2005;38(5):545-552.
8. Kozal MJ, Amico KR, Chiarella J, et al.:Antiretroviral resistance and high-risk transmission behavior among HIV-positive patients in clinical care. AIDS 2004;18(16):2185-2189.
9. Leigh Brown AJ, Frost SD, Mathews WC, et al.: Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J Infect Dis 2003;187(4):683-686.
10. Vercauteren J, Wensing AM, van de Vijver DA, et al.: Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis 2009;200(10):1503- 1508.
11. Weinstock HS, Zaidi I, Heneine W, et al.: The epidemiology of antiretroviral drug resistance among drug-naive HIV-1- infected persons in 10 US cities. J Infect Dis 2004;189(12): 2174-2180.
12. Bartmeyer B, Kuecherer C, Houareau C, et al.: Prevalence of transmitted drug resistance and impact of transmitted resistance on treatment success in the German HIV-1 Seroconverter Cohort. PLoS One 2010;5(10):e12718.
13. Bracciale L, Colafigli M, Zazzi M, et al.: Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy: Evolution over 12 years and predictors. J Antimicrob Chemother 2009;64(3):607-615.
14. Burchell AN, Bayoumi AM, Rourke SB, et al.: Increase in transmitted HIV drug resistance among persons undergoing genotypic resistance testing in Ontario, Canada, 2002-09. J Antimicrob Chemother 2012;67(11):2755-2765.
15. Cane P, Chrystie I, Dunn D, et al.: Time trends in primary resistance to HIV drugs in the United Kingdom: Multicentre observational study. BMJ 2005;331(7529):1368.
16. Jain V, Liegler T, Vittinghoff E, et al.: Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009. PLoS One 2010;5(12):e15510.
17. Karlsson A, Bjorkman P, Bratt G, et al.: Low prevalence of transmitted drug resistance in patients newly diagnosed with HIV-1 infection in Sweden 2003-2010. PLoS One 2012;7(3):e33484.
18. Kousiappa I, Achilleos C, Hezka J, et al.: Molecular characterization of HIV type 1 strains from newly diagnosed patients in Cyprus (2007-2009) recovers multiple clades including unique recombinant strains and lack of transmitted drug resistance. AIDS Res Hum Retroviruses 2011; 27(11):1183-1199.
19. Kousiappa I, van de Vijver DA, Demetriades I, and Kostrikis LG: Genetic analysis of HIV type 1 strains from newly infected untreated patients in Cyprus: High genetic diversity and low prevalence of drug resistance. AIDS Res Hum Retroviruses 2009;25(1):23-35.
20. Skoura L, Metallidis S, Buckton AJ, et al.: Molecular and epidemiological characterization of HIV-1 infection networks involving transmitted drug resistance mutations in Northern Greece. J Antimicrob Chemother 2011;66(12):2831-2837.
21. Vercauteren J, Derdelinckx I, Sasse A, et al.: Prevalence and epidemiology of HIV type 1 drug resistance among newly diagnosed therapy-naive patients in Belgium from 2003 to 2006. AIDS Res Hum Retroviruses 2008;24(3):355-362.
22. Chun TW, Justement JS, Moir S, et al.: Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: Implications for eradication of virus. J Infect Dis 2007;195(12):1762-1764.
23. Finzi D, Blankson J, Siliciano JD, et al.: Latent infection of CD4 + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999;5(5):512-517.
24. Finzi D, Hermankova M, Pierson T, et al.: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997;278(5341):1295-1300.
25. Sedaghat AR, Siliciano RF, and Wilke CO: Low-level HIV-1 replication and the dynamics of the resting CD4 + T cell reservoir for HIV-1 in the setting of HAART. BMC Infect Dis 2008;8:2.
26. Siliciano JD, Kajdas J, Finzi D, et al.: Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4 + T cells. Nat Med 2003;9(6):727-728.
27. Kostrikis LG, Touloumi G, Karanicolas R, et al.: Quantitation of human immunodeficiency virus type 1 DNA forms with the second template switch in peripheral blood cells predicts disease progression independently of plasma RNA load. J Virol 2002;76(20):10099-10108.
28. Goujard C, Bonarek M, Meyer L, et al.: CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients. Clin Infect Dis 2006;42(5):709-715.
29. Katzenstein TL, Oliveri RS, Benfield T, Eugen-Olsen J, Nielsen C, and Gerstoft J: Cell-associated HIV DNA measured early during infection has prognostic value independent of serum HIV RNA measured concomitantly. Scand J Infect Dis 2002;34(7):529-533.
30. Minga AK, Anglaret X, d'Aquin Toni T, et al.: HIV-1 DNA in peripheral blood mononuclear cells is strongly associated with HIV-1 disease progression in recently infected West African adults. J Acquir Immune Defic Syndr 2008; 48(3):350-354.
31. Rouzioux C, Hubert JB, Burgard M, et al.: Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4 + T cell counts. J Infect Dis 2005; 192(1):46-55.
32. Tierney C, Lathey JL, Christopherson C, et al.: Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy. J Infect Dis 2003;187(1):144-148.
33. Demetriou VL, van de Vijver DA, Kousiappa I, et al.: Cellular HIV-1 DNA levels in drug sensitive strains are equivalent to those in drug resistant strains in newly-diagnosed patients in Europe. PLoS One 2010;5(6):e10976.
34. Antoniadou ZA, Kousiappa I, Skoura L, et al.: Molecular epidemiology of HIV-1 infection in northern Greece (2009-2010): Evidence of a transmission cluster of HIV-1 subtype A1 drug resistant strains among men having sex with men. AIDS Res Hum Retroviruses. 2013. [Epub ahead of print]; DOI:10.1089/aid.2013.0166.
35. Kostrikis LG, Bagdades E, Cao Y, Zhang L, Dimitriou D, and Ho DD: Genetic analysis of human immunodeficiency virus type 1 strains from patients in Cyprus: Identification of a new subtype designated subtype I. J Virol 1995;69(10):6122-6130.
36. Sing T, Low AJ, Beerenwinkel N, et al.: Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Antivir Ther 2007;12(7):1097-1106.
37. Jensen MA, Coetzer M, van 't Wout AB, Morris L, and Mullins JI: A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope V3 sequences. J Virol 2006;80(10):4698-4704.
38. Jensen MA, Li FS, van't Wout AB, et al.: Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 2003;77(24): 13376-13388.
39. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, and Kumar S: MEGA5: Molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 2011;28(10): 2731-2739.
40. Gifford RJ, de Oliveira T, Rambaut A, et al.: Phylogenetic surveillance of viral genetic diversity and the evolving molecular epidemiology of human immunodeficiency virus type 1. J Virol 2007;81(23):13050-13056.
41. Tsiara CG, Nikolopoulos GK, Bagos PG, et al.: Impact of HIV type 1 DNA levels on spontaneous disease progression: A meta-analysis. AIDS Res Hum Retroviruses 2012;28(4): 366-373.